HRMY Q3 2024 Earnings — Harmony Biosciences Holdings, Inc. Revenue & Financial Results | Market Cap Arena

HRMYHarmony Biosciences Holdings, Inc.

$2B

Q3 2024 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$186M+16.1% YoY

Gross Profit

$143M77.0% margin

Operating Income

$62M33.2% margin

Net Income

$46M24.8% margin

EPS (Diluted)

$0.79

QoQ Revenue Growth

+7.7%

Cash Flow

Operating Cash Flow

$71M

Free Cash Flow

$70M

Stock-Based Comp.

$11M

Balance Sheet

Total Assets

$928M

Total Liabilities

$331M

Stockholders' Equity

$597M

Cash & Equivalents

$387M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$186M	$160M	+16.1%
Gross Profit	$143M	$128M	+11.9%
Operating Income	$62M	$65M	-4.3%
Net Income	$46M	$38M	+19.8%